3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
3
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
37
Colorectal Neoplasms
16
Liver Neoplasms
10
Biliary Tract Neoplasms
10
Cholangiocarcinoma
7
Pancreatic Neoplasms
6
Adenocarcinoma Of Esophagus
6
Stomach Neoplasms
5
Diabetes Mellitus, Insulin-Dependent, 12
4
Squamous Cell Carcinoma of Head and Neck
3
Melanoma
3
Esophageal Squamous Cell Carcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Unresectable Hepatocellular Carcinoma
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Cancer Non-resectable
1
Microsatellite Instability
1
Interventions
pembrolizumab
29
Carboplatin
10
Surveys and Questionnaires
9
Paclitaxel
9
Trastuzumab
8
Nivolumab
8
Cisplatin
8
Taxes
7
Gemcitabine
7
Bevacizumab
6
Specimen Handling
5
Oxaliplatin
5
Irinotecan
5
Fluorouracil
5
Cetuximab
5
Biopsy
5
spartalizumab
4
Leucovorin
4
Ipilimumab
4
Docetaxel
4
Cyclophosphamide
4
tisotumab vedotin
3
fludarabine
3
durvalumab
3
atezolizumab
3
aldesleukin
3
X-Rays
3
Psychiatric Rehabilitation
3
Magnetic Resonance Spectroscopy
3
Interviews as Topic
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
tremelimumab
×
Gastrointestinal
×
Clear all
NCT06680739
2026-06-01
SERPENTINE
Vall d'Hebron Institute of Oncology
Phase 2
Recruiting
60 enrolled